ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumoniaIgnacio Martín‐Loeches, Richard G. Wunderink, Antoni Torres et al.|Intensive Care Medicine|2023Cited by 289
Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised PatientsMarta Francesca Di Pasquale, Milena Encheva, Giovanni Sotgiu et al.|Clinical Infectious Diseases|2018Cited by 256
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumoniaIgnacio Martín‐Loeches, Richard G. Wunderink, Antoní Torres et al.|European Respiratory Journal|2023Cited by 139
Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registryGiorgio Walter Canonica, Massimo Triggiani, Diego Bagnasco et al.|World Allergy Organization Journal|2019Cited by 119
Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumoniaForest W. Arnold, Jordi Rello, Gustavo Lopardo et al.|Respiratory Medicine|2018Cited by 23